Using Viruses to Boost Mesothelioma Immunotherapy

Immunotherapy through clinical trials is becoming a promising treatment option for some mesothelioma patients. Checkpoint inhibitor drugs, such as Keytruda, already have U.S. Food and Drug Administration (FDA) approval as first-line treatments for non-small cell lung cancer (NSCLC), edging immunotherapy drugs closer to becoming a viable second-line therapy for other thoracic cancers, including pleural mesothelioma. However, overall response to immune therapies remains relatively low. Researchers across the country are striving to enhance responsiveness to immunotherapy drugs. Leading that trend is viroimmunotherapy, or the process of combining cancer-killing (oncolytic) viruses with immunotherapy drugs. Dr. Manish Patel, an assistant professor in the division of hematology, oncology and transplantation at the University of Minnesota, has studied the potential of virus therapy for mesothelioma for several years. His research led to an ongoing clinical trial at the Mayo Clinic in Rochester, Minnesota, investigating the side effects and optimal dosage levels of using a genetically altered measles virus to kill mesothelioma tumor cells. Patel and Dr. Alexander Dash of Macalester College in St. Paul, Minnesota, recently published a paper in the journal Biomedicines that analyzes measles and other oncolytic viruses as potential viroimmunotherapy treatments for pleural mesothelioma and other thoracic cancers. As research continues, Patel believes the day of using viruses to in...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Biomedicines checkpoint blockade Checkpoint inhibitor drugs clinical trials for mesothelioma Dr. Alexander Dash Dr. Manish Patel FDA approval Keytruda immune response cancer immunotherapy response mesothelioma intratumoral injections k Source Type: news

Related Links:

Notch signaling is a highly conserved intercellular pathway with tightly regulated and pleiotropic roles in normal tissue development and homeostasis. Dysregulated Notch signaling has also been implicated in human disease, including multiple forms of cancer, and represents an emerging therapeutic target. Successful development of such therapeutics requires a detailed understanding of potential on-target toxicities. Here, we identify autosomal dominant mutations of the canonical Notch ligand Jagged1 (or JAG1) as a cause of peripheral nerve disease in 2 unrelated families with the hereditary axonal neuropathy Charcot-Marie-T...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Staphylococcus aureus remains a leading cause of human infection. These infections frequently recur when the skin is a primary site of infection, especially in infants and children. In contrast, invasive staphylococcal disease is less commonly associated with reinfection, suggesting that tissue-specific mechanisms govern the development of immunity. Knowledge of how S. aureus manipulates protective immunity has been hampered by a lack of antigen-specific models to interrogate the T cell response. Using a chicken egg OVA–expressing S. aureus strain to analyze OVA-specific T cell responses, we demonstrated that primary...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
States with the highest rates of melanoma cases linked to ultraviolet radiation are spread across the United States on the East and West coasts, in Hawaii and in landlocked states, according to a study published Monday in the International Journal of Cancer.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Measles may lead to serious, fatal complications not often associated with the disease, a new study finds.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
Patches made from human placenta could prevent men becoming impotent following prostate cancer surgery. Incontinence and erectile dysfunction can occur in up to seven in ten men.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Once thought to be"undruggable," a target in renal cell carcinoma now has a drug aimed at it, and initial results from a small clinical trial are promising.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
The highly contagious infection can lead to deadly complications, three of which were discussed in a report published today.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
This study confirms that EVs may represent an alternative to whole MSCs for aGvHD prevention, once the effective dose is reproducibly identified according to EV‐IFU and EV‐TD definition.
Source: Stem Cells - Category: Stem Cells Authors: Tags: Translational and Clinical Research Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Genetics | Hematology | Immunotherapy | Lung Cancer | Lung Transplant | Measles | Measles Vaccine | Melanoma | Mesothelioma | Non-Small Cell Lung Cancer | Skin Cancer | Study | Transplants | University of Minnesota | Vaccines | Veterinary Vaccinations | Virotherapy